April 2, 2026via The Verge AI
It’s not easy to get depression-detecting AI through the FDA
Why it matters
Regulatory hurdles remain a major obstacle for healthcare AI startups, even with promising technology. Kintsugi's failure to secure FDA clearance after 7 years highlights the challenges of bringing mental health AI to market.
Key signals
- Seven years of development
- Company shutting down due to FDA clearance failure
- Technology being released as open-source
- Pivot potential to deepfake audio detection
The hook
Seven years. $millions invested. Kintsugi's depression-detecting AI just hit the FDA wall and shut down.
For the past seven years, the California-based startup Kintsugi has been developing AI designed to detect signs of depression and anxiety from a person's speech. But after failing to secure FDA clearance in time, the company is shutting down and releasing most of its technology as open-source. Some elements may even find a second life beyond healthcare, like detecting deepfake audio.
Mental health assessments still largely rely on patient questionnaires and clinical interviews, rather than the lab tests or scans common in physical medicine. Instead of focusing on what someone is saying, Kintsugi's software analyzes how it is being said. Th …
Read the full story at The Verge.
Relevance score:85/100